Why It Matters
The U.S. Food and Drug Administration has officially recognized a nationwide supply constraint for estradiol transdermal patches, impacting women seeking hormone replacement therapy for menopause symptoms. This acknowledgment highlights the tension between surging consumer demand for menopausal care and manufacturing capacity limits.
What Happened
The FDA released a statement earlier this month confirming that estrogen-based hormonal patches are currently in short supply across the United States. This marks the first time the agency has listed these specific patches on its official shortage list, despite earlier indications of scarcity from industry groups.
The American Society of Health-System Pharmacists first identified the shortage in January, two months after the FDA removed a “black box” warning from the treatment. Regulatory changes often influence prescribing habits and patient uptake, contributing to rapid shifts in demand.
In its recent release, the FDA stated it is expediting actions to help manufacturers increase production. All six companies that produce these patches are currently working to expand their capacity and prioritize output to meet market needs.
“The FDA views increased interest in menopause treatment as an important development for women’s health and is working closely with manufacturers to help ensure that the supply of estradiol patches keeps pace with demand,” the agency said in its statement.
By the Numbers
six — number of manufacturers working to expand patch capacity
45 and 55 — typical age range for menopause occurrence
January — month pharmacists first noted the shortage
60 — pieces of menopause-related legislation introduced nationwide as of May
Twenty-six — states that have enacted menopause-related laws since 2019
Zoom Out
The supply issue coincides with a broader national shift in how healthcare systems and employers address menopause. The National Institute on Aging notes that menopause typically occurs between ages 45 and 55, bringing symptoms such as hot flashes, night sweats, bone density loss, and insomnia.
Estradiol patches replace estrogen lost during this transition, but access has become a legislative priority. As of May, more than 60 pieces of menopause-related legislation had been introduced nationwide. Twenty-six states have already enacted laws related to menopause care since 2019, focusing on insurance coverage mandates and workplace accommodations.
This regulatory activity reflects growing awareness of menopausal health as a distinct medical category rather than an inevitable life stage without clinical support. Lawmakers in Louisiana and other states are considering measures to protect rural hospital services and improve healthcare affordability for aging populations, including candidates pledging rural hospital protection in recent elections.
What’s Next
The FDA will continue monitoring manufacturing output as the six major producers attempt to scale up operations. Additional menopause-related bills are expected during upcoming 2027 legislative sessions, potentially expanding insurance requirements and employer obligations further. Patients may experience continued delays in obtaining patches until supply chains stabilize.